Brendan Technologies Chief Executive Officer to Present at Immunogenicity for Biotherapeutics Conference.

CARLSBAD, Calif. -- Brendan Technologies, Inc. (OTCBB: BDTE), an innovative analytical software company, said that Dr. John Dunn, founder and chief executive officer, will be hosting a half-day seminar entitled, Qualitative and Quantitative Tests for Neutralizing Antibodies, at the 8th Annual Immunogenicity for Biotherapeutics Conference in San Diego on May 8, 2007. This is the largest immunogenicity conference tracking assay development and validation, data analysis and regulatory considerations.

"Immunogenicity testing is a new market segment for Brendan, and a natural extension to the Company's current customer base," stated Dr. Dunn. "Brendan's advanced analytical software is required for the many challenges in immunogenicity testing." The Company is currently working on its next generation version of its StatLIA([R]) software product, which will make it scalable from a desktop version to an enterprise-wide automated solution for the laboratory and provide easy integration into OEM instrumentation. This new version will enable the company to better serve the growing needs of its customers.

Background on Immunoassay Testing

Immunoassays are highly sensitive and specific chemical tests used to detect and quantify extremely minute substances in blood, body fluid and other biological samples, using an immunological reaction. These tests measure the formation of antibody-antigen complexes and detect them via an indicator reaction. Their high specificity results from the use of antibodies and purified antigens as reagents. High sensitivity is achieved by using an indicator system that results in amplification of the measured product. Immunoassays may be qualitative (positive or negative) or quantitative (amount measured).

Immunoassays are one of the world's largest and fastest growing testing technologies used to diagnose diseases, discover new chemical entities and biological products, provide vital data in the development of drugs in FDA clinical trials, and assist in quality control of drug manufacturing and drug screening. It is also one of the largest technologies used in environmental testing. Currently, $50 billion is spent globally on immunoassay testing, with approximately $1 billion of that being spent on immunoassay software.

About Brendan Technologies, Inc.

Brendan Technologies, a developer and marketer of innovative analytical software, is actively providing software solutions to improve the accuracy, quality control, workflow, and regulatory compliance of immunoassay testing in laboratories in the biopharmaceutical, clinical, research, veterinarian and agricultural industries. The Company's customers, many of whom are Fortune 1000 organizations, represent some of the largest corporations in their respective fields. Brendan Technologies is currently redesigning and expanding its current product lineup to better capitalize on the growing demand of its target markets for more advanced software.

FORWARD-LOOKING STATEMENTS: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-KSB, as amended, for the most recently ended fiscal year. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward- looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.